Srikripa Devarakonda
Stock Analyst at Truist Securities
(3.04)
# 1,896
Out of 5,008 analysts
66
Total ratings
47.54%
Success rate
0.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $53 → $68 | $56.92 | +19.47% | 4 | Sep 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $583.24 | +39.22% | 8 | Aug 11, 2025 | |
| INCY Incyte | Maintains: Hold | $73 → $79 | $87.17 | -9.37% | 11 | Jul 30, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $9.30 | +18.28% | 1 | May 5, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $152.21 | +30.74% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $15.65 | +59.74% | 5 | Apr 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $65.49 | +16.05% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $843.63 | +23.04% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $232.83 | -6.80% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $26.27 | +21.81% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $15.14 | +230.25% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $39.50 | +13.92% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.85 | +2,826.83% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $9.00 | +66.67% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.83 | +266.23% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $60.17 | +16.34% | 4 | May 29, 2024 |
Kymera Therapeutics
Sep 30, 2025
Maintains: Buy
Price Target: $53 → $68
Current: $56.92
Upside: +19.47%
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $583.24
Upside: +39.22%
Incyte
Jul 30, 2025
Maintains: Hold
Price Target: $73 → $79
Current: $87.17
Upside: -9.37%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $9.30
Upside: +18.28%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $152.21
Upside: +30.74%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $15.65
Upside: +59.74%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $65.49
Upside: +16.05%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $843.63
Upside: +23.04%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $232.83
Upside: -6.80%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $26.27
Upside: +21.81%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $15.14
Upside: +230.25%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $39.50
Upside: +13.92%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.85
Upside: +2,826.83%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $9.00
Upside: +66.67%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $9.83
Upside: +266.23%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $60.17
Upside: +16.34%